ProShare Advisors LLC Has $21.44 Million Stake in Bristol Myers Squibb Company $BMY

ProShare Advisors LLC grew its stake in Bristol Myers Squibb Company (NYSE:BMY) by 3.5% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 397,535 shares of the biopharmaceutical company’s stock after buying an additional 13,369 shares during the quarter. ProShare Advisors LLC’s holdings in Bristol Myers Squibb were worth $21,443,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Darwin Wealth Management LLC bought a new stake in Bristol Myers Squibb during the second quarter worth approximately $25,000. Physician Wealth Advisors Inc. raised its holdings in Bristol Myers Squibb by 73.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 202 shares during the period. EQ Wealth Advisors LLC acquired a new position in Bristol Myers Squibb during the 4th quarter worth $32,000. KERR FINANCIAL PLANNING Corp bought a new stake in Bristol Myers Squibb during the third quarter valued at about $35,000. Finally, Garner Asset Management Corp acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at about $35,000. Institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the completion of the transaction, the executive vice president directly owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Wells Fargo & Company reissued an “outperform” rating and set a $60.00 price objective (up from $55.00) on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Sunday, April 19th. Cantor Fitzgerald lifted their price target on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 8th. HSBC upped their price target on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Finally, Guggenheim reissued a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and an average target price of $61.31.

Bristol Myers Squibb Stock Up 0.2%

Shares of BMY opened at $58.45 on Thursday. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The company has a 50-day simple moving average of $58.48 and a 200-day simple moving average of $55.73. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The firm has a market capitalization of $119.37 billion, a P/E ratio of 16.42, a P/E/G ratio of 0.17 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period last year, the business earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts expect that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were given a dividend of $0.63 per share. The ex-dividend date was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.3%. Bristol Myers Squibb’s payout ratio is currently 70.79%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb announced a strategic agreement with Anthropic to make Claude Enterprise available across its global operations, including more than 30,000 employees, with use cases spanning research, drug development, manufacturing, and commercial functions. The deal may help accelerate discovery and lower operating friction. Article Title
• Positive Sentiment: Multiple reports confirmed Bristol Myers Squibb is deploying Anthropic’s Claude AI tools to speed up drug discovery and broaden AI adoption across the company, reinforcing the market’s view that BMY is investing in productivity-enhancing technology. Article Title
• Positive Sentiment: Tempus AI also announced an expanded collaboration with Bristol Myers Squibb to improve clinical trial design and increase the probability of success across five development programs, which supports the company’s pipeline execution story. Article Title
• Neutral Sentiment: Coverage pieces from Seeking Alpha, Yahoo Finance, and Zacks indicate BMY is a closely watched stock right now, but these items appear more descriptive than fundamentally new. Article Title
• Neutral Sentiment: Recent commentary also continues to focus on pipeline hopes, patent risks, and valuation moves, which keep investor attention on long-term execution rather than near-term financial results. Article Title

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.